Background-Pressure overload resulting from aortic stenosis causes maladaptive ventricular and vascular remodeling that can lead to pulmonary hypertension, heart failure symptoms, and adverse outcomes. Retarding or reversing this maladaptive remodeling and its unfavorable hemodynamic consequences has the potential to improve morbidity and mortality. Preclinical models of pressure overload have shown that phosphodiesterase type 5 inhibition is beneficial; however, the use of phosphodiesterase type 5 inhibitors in patients with aortic stenosis is controversial because of concerns about vasodilation and hypotension. Methods and Results-We evaluated the safety and hemodynamic response of 20 subjects with severe symptomatic aortic stenosis (mean aortic valve area, 0.7Ϯ0.2 cm 2 ; ejection fraction, 60Ϯ14%) who received a single oral dose of sildenafil (40 or 80 mg). Compared with baseline, after 60 minutes, sildenafil reduced systemic (Ϫ12%; PϽ0.001) and pulmonary (Ϫ29%; Pϭ0.002) vascular resistance, mean pulmonary artery (Ϫ25%; PϽ0.001) and wedge (Ϫ17%; PϽ0.001) pressures, and increased systemic (13%; PϽ0.001) and pulmonary (45%; PϽ0.001) vascular compliance and stroke volume index (8%; Pϭ0.01). These changes were not dose dependent. Sildenafil caused a modest decrease in mean systemic arterial pressure (Ϫ11%; PϽ0.001) but was well tolerated with no episodes of symptomatic hypotension. Conclusions-This study shows for the first time that a single dose of a phosphodiesterase type 5 inhibitor is safe and well tolerated in patients with severe aortic stenosis and is associated with improvements in pulmonary and systemic hemodynamics resulting in biventricular unloading. These findings support the need for longer-term studies to evaluate the role of phosphodiesterase type 5 inhibition as adjunctive medical therapy in patients with aortic stenosis. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01060020. (Circulation. 2012;125:2353-2362.) The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
C alcific aortic stenosis (AS) is considered a surgical disease. No medical therapy has been proven to delay/ reverse the progression of disease, symptoms, or time to valve replacement. 1 Although attempts at medical therapy have focused on slowing progressive stenosis of the valve, prospective clinical trials with statin medications have yielded disappointing results with regard to this end point. 2, 3 However, it bears emphasis that AS is more than simply a disease of the valve in that the progressive remodeling of the left ventricle (LV) and vasculature (pulmonary and systemic) that occurs secondary to pressure overload also contributes to significant morbidity and mortality in patients with AS. 4 -6 
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Maintenance of cardiac output in AS imposes a long-term increase in LV pressure that leads to ventricular remodeling (characterized by myocyte hypertrophy and myocardial fibrosis) and eventually diastolic and systolic dysfunction. This pressure overload caused by valvular stenosis is often exacerbated by systemic hypertension, which causes an additional load on the LV. 4 Diastolic dysfunction of the hypertrophied ventricle causes elevated LV filling pressures, which are transmitted to the pulmonary vasculature, causing pulmonary venous congestion and associated heart failure symptoms. 7 Group II pulmonary hypertension (PH) develops in a majority of patients with AS, becoming severe in 15% to 20%. 8, 9 Additionally, some patients with AS and PH develop a "reactive" or precapillary component to their PH, characterized by an elevated pulmonary vascular resistance (PVR). 7 Patients treated with valve replacement have worse outcomes when there is associated hypertrophic LV remodeling, diastolic dysfunction, and PH. 6,10 -12 Although it would be ideal to treat all patients with AS in the "golden window" as they become symptomatic, the clinical reality is that AS often is not recognized until after physiological compensatory mechanisms have been exhausted and patients present with advanced symptoms, making them either inoperable or at increased risk for a poor surgical outcome. 13 Accordingly, retarding or reversing the maladaptive remodeling and its unfavorable hemodynamic consequences represents a significant unmet clinical need. 1 Existing experimental and clinical studies raise the interesting possibility that phosphodiesterase type 5 (PDE5) inhibition may both favorably alter the abnormal hemodynamic profile and retard or reverse maladaptive remodeling in patients with AS. A preclinical model of pressure overload demonstrated that sildenafil both blunted the development of cardiac hypertrophy and fibrosis and reversed preestablished hypertrophic remodeling while improving LV function. 14 Studies in patients with nonvalvular left-sided heart failure have shown that PDE5 inhibition can unload the failing heart, improve pulmonary hemodynamics, and increase exercise capacity after a single dose. 15, 16 Long-term PDE5 inhibition has led to improved diastolic and systolic function, decreased LV mass and PVR, and improvements in quality of life and functional capacity. [17] [18] [19] [20] However, there has been reluctance to use vasodilating medications such as PDE5 inhibitors in patients with AS because of concerns about precipitating hypotension. Although the Use of Nitroprusside in Left Ventricular Dysfunction and Obstructive Aortic Valve Disease (UNLOAD) study showed that an intravenous vasodilator is safe and welltolerated in patients with severe AS, the intensive monitoring required and rapid tolerance of this approach limit its utility in routine clinical practice. 21 Accordingly, the objective of this study was to assess the short-term hemodynamic response to and safety and tolerability of orally administered sildenafil in patients with severe AS.
Methods

Patients
We enrolled patients Ն18 years of age with severe calcific AS (aortic valve area Ͻ1.0 cm 2 ) undergoing right and left heart catheterization for clinical reasons. Exclusion criteria were nitrate use within 24 hours, systolic blood pressure Ͻ110 mm Hg, mean systemic arterial pressure Ͻ75 mm Hg, severe mitral or aortic regurgitation, retinal or optic nerve problems, ␣-antagonist medication use within 24 hours, recent (Յ30 days) acute coronary syndrome, and oxygen saturation Ͻ90% on room air. Institutional Review Board approval was obtained, and all patients signed informed consent before catheterization.
Clinical Data
Clinical variables were obtained at the time of the cardiac catheterization from medical records and through patient interviews. Definitions for the clinical variables are given in the online-only Data Supplement.
Hemodynamic Measurements
At each time point (baseline and 30 and 60 minutes after the administration of sildenafil), hemodynamic measurements were taken in triplicate (the average was reported) at end expiration with a fluid-filled balloon-tipped 7.5F Swan-Ganz catheter for right-sided pressures and a 4F pigtail catheter in the descending aorta for systemic pressures. Cardiac output was determined by the Fick method, with the Lafarge formula used to estimate oxygen consumption. Standard hemodynamic variables were calculated from established formulas. Valvuloarterial impedance, a measure of global LV load, was also determined, given its association with reduced LV function and survival in patients with AS. 22, 23 Formulas are shown in the online-only Data Supplement.
Study Protocol
Medications with vasoactive or diuretic effects were withheld for 12 to 24 hours before the heart catheterization. No supplemental oxygen, sedatives, or pain medications (other than local anesthetics) were administered until after the pressures were measured 60 minutes after administration of sildenafil. After baseline right and left heart hemodynamic measurements were made, a single oral dose of sildenafil (40 or 80 mg) was given. Because of the possibility of a differential response to sildenafil based on ventricular function, each dose (40 or 80 mg) was distributed equally among those with reduced (ejection fraction [EF] Ͻ50%) or preserved (EF Ն50%) LV function. We anticipated that 30% of our subjects (nϭ6) would have a reduced EF and 70% (nϭ14) would have a preserved EF. Of those with a reduced EF, the first 3 subjects received 40 mg sildenafil, and the next 3 subjects were administered 80 mg. Of those with a preserved EF, the first 5 subjects received 40 mg, the next 5 subjects received 80 mg, and the doses were alternated for the remaining 4 subjects enrolled with a preserved EF. Repeat hemodynamic measurements were performed 30 and 60 minutes after sildenafil was administered. An echocardiogram was performed immediately before the catheterization, and select images were repeated 50 to 60 minutes after administration of sildenafil.
Adverse Events
Any adverse events were recorded, including hypotension (defined as mean systemic arterial pressure decrease by Ͼ20% and mean systemic arterial pressure decrease to Ͻ65 mm Hg), symptomatic hypotension, syncope, arrhythmia (significant atrial or ventricular arrhythmias that either were new in onset or required intervention), or administration of a vasoconstrictor medication. Any side effects were also recorded. Patients were monitored for 3 hours after the drug was administered.
Echocardiographic Data
Parasternal and apical views were used to acquire standard 2-dimensional and Doppler images on a GE Vivid 7 ultrasound system. The severity of AS was determined by measuring mean and peak gradients across the valve with the modified Bernoulli equation and by calculating aortic valve area with the continuity equation. Measurements of LV chamber dimensions, relative wall thickness, LV mass, EF, systolic excursion velocity (LV SЈ), early diastolic mitral annular velocity (eЈ), and determination of valve regurgitation were made as recommended by the American Society of Echocardiography and described previously. 24 -26 LV mass was indexed to body surface area. LV midwall shortening was calculated from 2-dimensional linear measurements made at end diastole and end systole. Midwall shortening was corrected for afterload, measured as circumferential end-systolic stress. 27 Stress-corrected midwall shortening was reported, reflecting the ratio of actual to predicted midwall shortening for the actual circumferential end-systolic stress. 22 Stan-dard 2-dimensional images were analyzed with GE EchoPac analysis software (versions 7.2 and 108.1.5; GE Vingmed Ultrasound AS, Horten, Norway) to measure LV longitudinal strain, strain rate, rotation, and twist with the speckle tracking method as described previously. 26 Right ventricular (RV) function was assessed from systolic excursion velocity (RV SЈ), tricuspid annular plane systolic excursion, and RV Tei index per guideline recommendations. 28 Measurements of LV stiffness, viscoelasticity, and the loadindependent index of diastolic filling were made with the parameterized diastolic filling formalism as previously described and validated 29 -31 with the use of transmitral Doppler E waves recorded during different respiratory states (regular breathing and held expiration and inspiration). Echocardiographic measurements before and after sildenafil administration were made by the same echocardiographer who was blinded to whether the images were obtained before or after drug administration.
Statistical Analysis
This was a single-center open-label study in which a single oral dose of sildenafil (40 or 80 mg) was administered at the time of right and left heart catheterization. The primary end point of the study was the change in mean pulmonary artery pressure (mPAP) from baseline to 60 minutes after sildenafil administration. All data are reported as meanϮSD except when indicated. Hemodynamic and ventricular function changes from baseline to 60 minutes were evaluated with the Wilcoxon signed-ranks test. Group comparisons were conducted with the Mann-Whitney U test or the Fisher exact test as appropriate. Spearman correlations were used to examine the linear relationships between continuous variables. All tests of statistical significance were evaluated at a 2-sided significance level of 0.05. All statistical analyses were performed with SAS for Windows version 9.3 (SAS Institute, Inc, Cary, NC).
Results
Patients
Baseline characteristics of patients enrolled in the study (nϭ20) are shown in Table 1 . The average age of the patients was 86 years; 50% were female; aortic valve area was 0.65Ϯ0.2 cm 2 ; and the EF was 60Ϯ14%. Ninety percent of the patients were in New York Heart Association functional class III or IV, and 65% had coronary disease. The clinical characteristics for those with baseline mPAP Ͻ35 versus Ն35 mm Hg were similar except that systolic blood pressure was greater in those with mPAP Ն35 mm Hg ( Table 1 ). The clinical characteristics for those who received the 40-versus 80-mg dose of sildenafil were similar ( Table I in 
Effects of Sildenafil on LV Load and Systemic Hemodynamics
Hemodynamic responses to sildenafil at both 30 and 60 minutes are shown in Table 2 . Pulmonary capillary wedge pressure (PCWP) decreased 17% (from 24Ϯ7 to 19Ϯ8 mm Hg; PϽ0.001) 60 minutes after sildenafil administration compared with baseline. The magnitude of the decrease was not dependent on dose or baseline hemodynamic characteristics ( Figure I in the online-only Data Supplement). Systemic vascular resistance decreased 12% (27Ϯ8 to 22Ϯ6 Wood units; PϽ0.001), systemic arterial compliance increased 13% (0.57Ϯ0.20 to 0.66Ϯ0.21 mL/mm Hg; PϽ0.001), and valvuloarterial impedance decreased 11% (7.8Ϯ2.0 to 6.7Ϯ1.7 mm Hg ⅐ mL Ϫ1 ⅐ m Ϫ2 ; PϽ0.001) after sildenafil ( Table 2) . Mean systemic arterial pressure decreased 11% (108Ϯ15 to 94Ϯ16 mm Hg; PϽ0.001); how- ever, there was no significant correlation between baseline characteristics and percent change in mean systemic arterial pressure ( Table II in the online-only Data Supplement). Despite the decrease in PCWP, sildenafil administration was associated with an 8% increase in stroke volume index (29Ϯ6 to 31Ϯ6 mL; Pϭ0.01; Table 2 and Figure 1A) . Figure  1B through 1E shows that the increase in stroke volume after treatment with sildenafil correlated with a decrease in systemic (r s ϭϪ0.79, PϽ0.001; Figure 1B ) and pulmonary (r s ϭϪ0.51, Pϭ0.02; Figure 1C ) vascular resistance, as well as an increase in systemic (r s ϭ0.69, PϽ0.001; Figure 1D ) and pulmonary (r s ϭ0.63, Pϭ0.003; Figure 1E ) arterial compliance, but did not correlate with changes in systolic myocardial function measured by stress-corrected midwall shortening (r s ϭ0.31, Pϭ0.21; Figure 1F ).
Effects of Sildenafil on Pulmonary Vascular Hemodynamics
In the whole cohort, the mPAP decreased 25% from 37Ϯ11 mm Hg (baseline) to 27Ϯ9 mm Hg (60 minutes after sildenafil; PϽ0.001; Table 2 ). As shown in Figure 2A , all but 1 subject had a reduction in mPAP with sildenafil at 60 minutes compared with baseline. Among the 17 subjects with PH (mPAP Ն25 mm Hg) on baseline measurements, 14 (82%) improved by at least 1 category of severity of PH after sildenafil and 3 subjects improved by Ն2 categories ( Figure   2B ). Figure 2C shows that there was a significant decrease in mPAP regardless of the dose administered or baseline pulmonary vascular hemodynamics. There was also a decrease in PVR by 29% (3.5Ϯ2.8 to 2.2Ϯ1.1 Wood units; Pϭ0.002) and an increase in pulmonary arterial compliance (PAC) by 45% (2.1Ϯ1.1 to 2.8Ϯ1.2 mL/mm Hg; PϽ0.001; Table 2 ). The decrease in PVR was limited to those with an elevated baseline PVR ( Figure 3B ), whereas the increase in PAC was observed regardless of baseline hemodynamic characteristics ( Figure II in the online-only Data Supplement).
We also assessed whether there was a difference in the response to sildenafil among those with passive PH, defined as mPAP Ն25 mm Hg and PVR Ͻ3 Wood units (nϭ10), and those with reactive PH, defined as mPAP Ն25 mm Hg and PVR Ն3 Wood units (nϭ7). These 2 groups of patients had similar improvements in mPAP and PAC after sildenafil, but there were differences in the relative effects on PCWP and PVR (Figure 3 ).
Sildenafil showed relative selectivity for the pulmonary circulation with greater changes observed in pulmonary arterial pressure and compliance and in PVR than the corresponding measures in the systemic circulation ( Table 2 ). There were no differences in the percent changes of the pulmonary vascular hemodynamic variables on the basis of the dose of sildenafil administered, but there was a trend toward a greater decrease in valvuloarterial impedance and 
Responders Versus Nonresponders to Sildenafil
The response to sildenafil in the pulmonary circulation (mPAP, PCWP, and PAC) was consistently, albeit not uniformly, favorable ( Table 2, Figures 2 
and 3, and Figures I and II in the online-only Data Supplement)
; very few subjects had no/poor response to sildenafil in these pulmonary hemodynamic indices. The decrease in PVR after sildenafil was confined mostly to those with an abnormally elevated baseline PVR (PVR Ն3 Wood units; Figure 3 ). In those patients (nϭ7), the reduction in PVR was uniform with a minimum decrease of 35%. Although the effects of sildenafil on the systemic circulation were also favorable, there were more subjects who had either no response or a blunted response in the systemic hemodynamic indices. There was a median decrease in systemic vascular resistance after sildenafil of 12%, but 2 subjects had an increase in systemic vascular resistance (Ͻ3%) and 6 subjects had a decrease of Ͻ10%. Likewise, although there was a median increase in systemic arterial compliance of 13%, 1 subject had a decrease in systemic arterial compliance (6%), and 7 subjects had an increase of Ͻ10%. Of the 18 subjects with valvuloarterial impedance measured before and after sildenafil, there was a median decrease in valvuloarterial impedance of 11%; however, 2 subjects had an increase in valvuloarterial impedance (Ͻ4%), and 7 subjects had a decrease of Ͻ10%. Although there was a median increase in stroke volume index of 8%, 6 subjects did not have any increase after sildenafil.
Effects of Sildenafil on LV and RV Function
Echocardiographic measures of LV and RV function before and 60 minutes after the administration of sildenafil are shown in Table 3 . No changes were observed in LV diastolic function, and there were no changes in radial or longitudinal measures of systolic function or LV twist. There was a trend toward improved global RV function as measured by the RV Tei index (Pϭ0.06), but there was no change in RV systolic function.
Adverse Events and Side Effects
Three subjects met the prespecified criteria for adverse events. Two subjects experienced hypotension as defined by the study protocol; however, these episodes were transient, were not associated with symptoms, and did not require any intervention. One subject had a supraventricular arrhythmia during the angiographic portion of the catheterization when the left main coronary artery was engaged with a catheter. After the catheter was removed, the arrhythmia ceased and no intervention or hemodynamic instability occurred. One other subject experienced a hypertensive emergency associated with pulmonary edema requiring noninvasive ventilation after receiving the angiographic contrast load. This patient tolerated the 60-minute period of hemodynamic monitoring after receiving sildenafil without difficulty. The only side effects from sildenafil reported were transient shortness of breath (1 subject) and rhinorrhea (2 subjects).
Discussion
This single-center hemodynamic study shows for the first time that a single dose of a PDE5 inhibitor is safe and well tolerated in patients with severe symptomatic AS and improves hemodynamics in the pulmonary and systemic circulations. Sildenafil unloaded the LV as it decreased afterload and preload and increased stroke volume without a change in heart rate. This unloading was associated with a modest decrease in systemic blood pressure. There were also significant, favorable changes in the pulmonary vasculature from sildenafil, including a 25% decrease in pulmonary artery pressures, a 29% decrease in PVR, and a 45% increase in pulmonary artery compliance. Taken together, these findings suggest that PDE5 inhibition is safe in patients with symptomatic AS and raise the possibility that PDE5 inhibitors may be useful as adjunctive medical therapy in AS to stabilize patients with advanced heart failure symptoms by improving abnormal hemodynamics.
Sildenafil Ameliorates Abnormal Hemodynamics in AS by Unloading the Heart and Favorable Effects in the Pulmonary Vasculature
Sildenafil Unloads the Heart It has long been recognized that patients with AS develop concentric hypertrophy secondary to pressure overload. The stenotic valve presents a relatively fixed orifice and is usually the dominant cause of the pressure-overload state. This has led to the still widely held notion that the afterload in AS is a fixed afterload, which has led to the classic teaching that vasodilators are relatively contraindicated in AS. 32 More recent studies, however, have suggested that increased vascular afterload adds to the LV afterload in patients with AS and may contribute to adverse patient outcomes. 23, 33 The UNLOAD study challenged prevailing dogma and showed that in critically ill patients with severe AS, severe LV dysfunction (EF Ϸ20%), and decompensated heart failure, an intravenous vasodilator (nitroprusside) was well tolerated and associated with unloading of the LV: decreased systemic vascular resistance, decreased PCWP, and increased stroke volume accompanied by a modest decrease in systemic pressure. 21 Here, we confirm these earlier findings and extend them by showing similar immediate unloading effects during cardiac catheterization in patients with severe symptomatic AS using an oral medication that has vasodilating properties. The observation that stroke volume increased despite a decrease in PCWP can be explained by a decrease in afterload and/or an increase in contractility. Given that there was no change in LV systolic myocardial function after sildenafil ( Figure 1F) , the most likely explanation for our findings is that sildenafil led to peripheral unloading of the LV ( Figure  1B and 1D) . Importantly, these data suggest that afterload is not necessarily fixed in patients with symptomatic AS and that reducing vascular afterload may improve hemodynamics in these patients. Sildenafil was also associated with significant unloading of the RV. Because RV dysfunction has been shown to be a predictor of poor outcome in high-risk valve surgery, 34 the unloading of the RV with sildenafil may have beneficial consequences. Although not measured directly, the reduction in preload and afterload with sildenafil (with no change in heart rate or contractility) might be expected to reduce myocardial oxygen demand and to allow the heart to function in a more optimal energetic state, potentially mitigating adverse cardiac remodeling over time.
Although sildenafil led to favorable unloading of the heart, we did not observe any immediate changes in diastolic or systolic function from 1 dose of drug consistent with prior studies. 15 However, it is important to note that PDE5 is expressed in the hypertrophied LV and RV and long-term PDE5 inhibition can improve diastolic and systolic function. 18, 19, 35 The mechanisms for improved load-independent diastolic and systolic function may require greater tissue penetration or alterations in signaling pathways and myocardial structure that take Ͼ60 minutes.
Sildenafil Improves Pulmonary Vascular Hemodynamics
PH is common in patients with severe AS (affecting 50%-65%) and is usually characterized as pulmonary venous hypertension, driven by the elevated filling pressures in the left side of the heart causing a passive increase in pulmonary artery pressures. 6, 7 In a significant minority, however, there also appears to be a reactive response in the pulmonary vasculature characterized by increased vascular resistance. 7 PH delineates a group of patients at increased risk, and no medical therapy particularly targets this pathophysiology in patients with AS. 6 In this regard, our results demonstrating a significant improvement in pulmonary vascular hemodynamics with sildenafil may have important implications. There was a consistent Ϸ25% decrease in pulmonary artery pressures in patients with severe AS, which did not depend on subjects having an elevated baseline mPAP or PVR. Sildenafil also decreased PVR by 52% in those with PVR Ն3 Wood units, likely because of improved cGMP release across the pulmonary vascular bed with sildenafil. 36 Additionally, the 45% increase in PAC with sildenafil may improve patient outcomes as PAC is an independent predictor of mortality in patients with pulmonary arterial hypertension. 37
Clinical Implications
Reversing the Decompensated Hemodynamic State
Advanced heart failure symptoms are associated with increased operative risk in patients with AS. 13 These patients are often characterized by pulmonary venous congestion, PH, afterload mismatch, and a low-output state. In some cases, the PH is so severe and the PVR so elevated that patients are considered inoperable, particularly if they are deemed to have irreversible PH as determined by a vasodilator study. Others will not receive an operation because of the severity of comorbidities or patient refusal. 38 The need for medical therapy to reverse this abnormal and deleterious hemodynamic state to decrease operative risk or to relieve symptoms in those not undergoing surgical correction is a significant unmet clinical need. 1 Diuretics are sometimes avoided because of concerns that patients with AS are preload dependent. If diuretics are used, they have little ability to address the breadth of hemodynamic abnormalities (because it is not just a volume-overload problem) and can precipitate renal dysfunction in elderly patients with limited renal reserve. Nitroprusside improves hemodynamics quickly, but it is an intravenous medication that requires intensive monitoring in an intensive care unit and leads to rapid tolerance and toxicity. 21 Our results suggest that PDE5 inhibition has the potential to address this unmet clinical need in ambulatory patients, insofar as sildenafil unloads both the LV and RV and is associated with a significant decrease in pulmonary vascular load. Unlike other vasodilators that dilate only systemic or pulmonary vascular circulations, our results suggest that the reduction in both systemic vascular resistance and PVR with PDE5 inhibition may offer a particular advantage for treating patients with decompensated AS. Thus, it is interesting to consider whether the administration of a PDE5 inhibitor to patients with AS in a decompensated clinical and hemodynamic state may reverse abnormal hemodynamics, reduce patient symptoms, and/or reduce operative risk by allowing for stabilization of the patient. It is important to remember, however, that in patients with coronary disease or heart failure, the combination of nitrates and PDE5 inhibitors is contraindicated.
Retarding or Reversing Maladaptive Remodeling
Even when valve replacement is performed, outcomes are worse in patients with preoperative evidence of maladaptive remodeling in the LV and pulmonary vasculature. 6,10 -12 Reverse remodeling can occur after the valve replacement relieves the pressure overload on the heart, but this reversal is often incomplete, which is associated with less symptomatic improvement and decreased survival. 6,39 -41 Although speculative, experimental pressure-overload studies 14 and emerging clinical studies with PDE5 inhibition in non-AS heart failure populations [17] [18] [19] [20] raise the interesting possibility that longer-term treatment with PDE5 inhibitors before aortic valve surgery may lead to favorable remodeling of the ventricle and pulmonary vasculature and potentially improve long-term surgical outcomes. Although other vasodilators may unload the LV, PDE5 inhibitors also directly affect myocardial biology in a way that improves cardiac remodeling. 14 Whether such a strategy could also delay the onset of symptoms related to AS is of significant interest. The present study provides an initial report of the safety of PDE5 inhibition in patients with AS and should encourage longerterm studies to investigate these possibilities.
Limitations
This was a short-term hemodynamic study assessing the effects of 1 dose of sildenafil while other vasoactive medications were held and subjects were supine during a cardiac catheterization. Because antihypertensive medications were held and patients with lower blood pressure were excluded, the average blood pressure was quite elevated when sildenafil was administered. Therefore, these data cannot be applied directly to patients with AS and lower blood pressure. However, in a stratified analysis of those with higher versus lower baseline blood pressure, there were no differences in the hemodynamic effects of sildenafil (Table IV in the online-only Data Supplement). We did not obtain postadministration ECG or troponin values on our subjects, so we cannot rule out that the drop in diastolic blood pressure associated with sildenafil could have precipitated myocardial ischemia by decreasing the transmyocardial pressure gradient. However, the concomitant drop in PCWP suggests that the effect of sildenafil on coronary blood flow may have been neutral. Herrmann et al 42 evaluated coronary blood flow in stenosed and normal coronary vessels and found that sildenafil administration was associated with an improvement in coronary flow reserve and no change in the velocity of coronary blood flow. The UNLOAD study did not identify any ischemic changes on ECG in patients with severe AS receiving nitroprusside despite a modest decrease in systemic blood pressure. 21 Additionally, despite the fact that many of our subjects had significant coronary disease, none of them complained of chest discomfort after receiving sildenafil. This study was an important first step and demonstrated safety after one dose, but further studies are needed with longer-term PDE5 inhibition to determine tolerability when subjects are ambulating and taking other vasoactive medications.
Conclusions
This study shows for the first time that a single oral dose of a PDE5 inhibitor is safe and well tolerated in patients with severe AS and provides favorable short-term hemodynamic effects in the pulmonary and systemic circulations. Treatment with sildenafil decreased both LV preload and afterload and increased stroke volume without adverse consequences. Sildenafil also significantly improved pulmonary artery pressure, PVR, and pulmonary arterial compliance and thus unloaded the RV. Therefore, these results raise the intriguing possibility that PDE5 inhibition may be useful as adjunctive AVA indicates aortic valve area; LV, left ventricular; SЈ, systolic excursion velocity; scMWS, stress-corrected midwall shortening; eЈ, early diastolic mitral annular velocity (average of lateral and septal); LIIDF, load-independent index of diastolic filling; RV, right ventricle; and TAPSE, tricuspid annular plane systolic excursion. Data are expressed as meanϮSD.
*Based on Wilcoxon signed-ranks test.
medical therapy in patients with symptomatic AS. Perhaps the administration of a PDE5 inhibitor to patients with AS in a decompensated clinical and hemodynamic state may improve abnormal hemodynamics, reduce patient symptoms, and/or reduce operative risk by allowing for stabilization of the patient. To evaluate these potential clinical benefits, longer-term studies are needed to assess the safety and efficacy of PDE5 inhibition in this patient population.
